Anti-MLH1 抗体 [EPR3893] (ab108622)

製品の概要

  • 製品名Anti-MLH1 antibody [EPR3893]
    MLH1 一次抗体 製品一覧
  • 製品の詳細
    Rabbit monoclonal [EPR3893] to MLH1
  • アプリケーション適用あり: WBmore details
    適用なし: Flow Cyt,IHC-P or IP
  • 種交差性
    交差種: Mouse, Rat, Human
  • 免疫原

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive)

  • ポジティブ・コントロール
    • 293T, Jurkat, K562 and SH-SY5Y cell lysates
  • 特記事項

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab108622 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB 1/1000 - 1/10000. Detects a band of approximately 85 kDa (predicted molecular weight: 85 kDa).
  • 追加情報Is unsuitable for Flow Cyt,IHC-P or IP.
  • ターゲット情報

    • 機能Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
    • 組織特異性Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
    • 関連疾患Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2) [MIM:609310]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
      Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
      Defects in MLH1 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
      Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.
      Defects in MLH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
      Note=Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.
    • 配列類似性Belongs to the DNA mismatch repair mutL/hexB family.
    • 細胞内局在Nucleus.
    • Information by UniProt
    • 参照データベース
    • 別名
      • COCA 2 antibody
      • COCA2 antibody
      • DNA mismatch repair protein Mlh1 antibody
      • FCC 2 antibody
      • FCC2 antibody
      • hMLH 1 antibody
      • hMLH1 antibody
      • HNPCC 2 antibody
      • HNPCC antibody
      • HNPCC2 antibody
      • MGC5172 antibody
      • MLH 1 antibody
      • MLH1 antibody
      • MLH1_HUMAN antibody
      • MutL homolog 1 (E. coli) antibody
      • MutL homolog 1 antibody
      • MutL homolog 1 colon cancer nonpolyposis type 2 antibody
      • MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody
      • MutL protein homolog 1 antibody
      • MutL, E. coli, homolog of, 1 antibody
      see all

    Anti-MLH1 antibody [EPR3893] 画像



    • Predicted band size : 85 kDa

      Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: MLH1 knockout HAP1 cell lysate (20 µg)
      Lane 3: HCT116 cell lysate (20 µg)
      Lane 4: 293T cell lysate (20 µg)
      Lanes 1 - 4: Merged signal (red and green). Green - ab108622 observed at 88 kDa. Red - loading control, ab8245, observed at 37 kDa.
      ab108622 was shown to recognize MLH1 when MLH1 knockout samples were used, along with additional cross-reactive bands. Wild-type and MLH1 knockout samples were subjected to SDS-PAGE. ab108622 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

    • All lanes : Anti-MLH1 antibody [EPR3893] (ab108622) at 1/1000 dilution

      Lane 1 : 293T cell lysate
      Lane 2 : Jurkat cell lysate
      Lane 3 : K562 cell lysate
      Lane 4 : SH-SY5Y cell lysate

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 85 kDa
    • All lanes : Anti-MLH1 antibody [EPR3893] (ab108622) at 1/1000 dilution

      Lane 1 : Hela Cells Whole Cell Lysates
      Lane 2 : HCT116 Whole Cell Lysates

      Lysates/proteins at 30 µg per lane.

      Secondary
      Goat Polyclonal to Rabbit IgG (HRP) at 1/2000 dilution
      Developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 85 kDa


      Exposure time : 30 seconds

      This image is courtesy of an anonymous abreview.

      See Abreview

    Anti-MLH1 antibody [EPR3893] (ab108622) 使用論文

    ab108622 has not yet been referenced specifically in any publications.

    Product Wall

    Application Western blot
    Sample Human Cell lysate - whole cell (Lane 1 - Hela, Lane 2- HCT116 cell lines)
    Gel Running Conditions Reduced Denaturing (4-12%)
    Loading amount 30 µg
    Specification Lane 1 - Hela, Lane 2- HCT116 cell lines
    Blocking step (agent) for 45 minute(s) · Concentration: 2% · Temperature: 37°C
    Username

    Abcam user community

    Verified customer

    投稿 Jul 13 2015

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"